Gyneco-Oncology Unit, Department of Obstetrics and Gynecology, Carmel Medical Center and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology and Clalit Health Services National Cancer Control Center, Haifa, Israel.
Gynecol Oncol. 2013 Sep;130(3):615-9. doi: 10.1016/j.ygyno.2013.05.025. Epub 2013 May 26.
The use of statins has been associated with reduced risk of malignancies in a variety of organ sites. This study was aimed at studying the effects of statins on gynecological cancers.
The Cancer in The Ovary and Uterus Study (CITOUS) is a case-control study of newly diagnosed cases of gynecological malignancies and age/sex/clinic/ethnic-group matched population controls. Use of statins prior to and following diagnosis was assessed in a subset of 424 cases of ovarian and endometrial cancers and 341 controls, enrolled in Clalit Health Services (CHS), using pharmacy records.
The use of statins for more than one year prior to diagnosis was associated with a significantly reduced risk of ovarian cancer (OR=0.56, 95% CI: 0.33-0.94) and of endometrial cancer (OR=0.59, 95% CI: 0.40-0.87). The association with endometrial cancer, but not with ovarian cancer (OR=0.54, 0.26-1.13), remained statistically significant after adjustment for fruit and vegetable consumption, sports activity, family history of endometrial and colorectal cancer, ethnicity, BMI, duration of breast feeding, age at 1st pregnancy and use of menopausal hormones (RR=0.48, 0.26-0.89). Women who used statins only after diagnosis of cancer had a significantly better survival of both ovarian cancer (Log rank test, p=0.021, age adjusted HR=0.47, 0.26-0.85) and endometrial cancer (p=0.06, age adjusted HR=0.45, 0.23-0.87).
The use of statins for more than one year before diagnosis was associated with a reduction in the risk of endometrial cancer and possibly ovarian cancer. A significantly improved survival of cases of both malignancies was noticed when statins were taken only after diagnosis.
他汀类药物的使用与各种器官部位的恶性肿瘤风险降低有关。本研究旨在研究他汀类药物对妇科癌症的影响。
卵巢和子宫癌研究（CITOUS）是一项新诊断的妇科恶性肿瘤病例对照研究，以及年龄/性别/诊所/种族匹配的人群对照。在 Clalit 健康服务中心（CHS）招募的 424 例卵巢癌和子宫内膜癌病例和 341 例对照中，使用药房记录评估了他汀类药物在诊断前和诊断后的使用情况。
在诊断前一年以上使用他汀类药物与卵巢癌（OR=0.56，95%CI：0.33-0.94）和子宫内膜癌（OR=0.59，95%CI：0.40-0.87）的风险显著降低相关。调整水果和蔬菜摄入、体育活动、子宫内膜癌和结直肠癌家族史、种族、BMI、母乳喂养持续时间、初产年龄和使用绝经激素后，与子宫内膜癌的相关性仍然具有统计学意义（RR=0.48，0.26-0.89），但与卵巢癌的相关性没有统计学意义（OR=0.54，0.26-1.13）。仅在癌症诊断后使用他汀类药物的女性，卵巢癌（对数秩检验，p=0.021，年龄调整 HR=0.47，0.26-0.85）和子宫内膜癌（p=0.06，年龄调整 HR=0.45，0.23-0.87）的生存情况显著更好。
在诊断前一年以上使用他汀类药物与子宫内膜癌和可能的卵巢癌风险降低有关。仅在诊断后使用他汀类药物时，两种恶性肿瘤的病例生存情况显著改善。
